Articles tagged with Hiv Research
The study aims to measure how effectively combination drug therapy works during the early stages of HIV infection, with a focus on reducing damage caused by the virus. Researchers hope to determine the optimal duration of treatment for maximum benefit and assess the impact of early treatment on immune system chemicals.
Researchers have found that cidofovir, a new antiviral drug, can slow the progression of cytomegalovirus (CMV) retinitis, a common cause of vision loss and blindness in AIDS patients. The study showed that both low and high doses of the drug were effective, allowing for less frequent treatment compared to traditional options.
Researchers found a three-drug combination of indinavir, zidovudine, and lamivudine significantly reduces AIDS symptoms and prolongs patient survival compared to two-drug combinations. The study enrolled 1,156 participants and showed a 45% reduction in disease progression events.
A recent NIH study found that a combination of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors can significantly reduce the occurrence of AIDS-defining illnesses or death. The study, ACTG 320, demonstrated improved survival and delayed disease progression in patients receiving triple combination therapy.
Researchers have identified key chemokine receptors that enable HIV to infect immune system cells, including CCR5 and CCR-3. Understanding these interactions could lead to the development of new treatments and prevention strategies for HIV/AIDS.